Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Decline in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large decline in short interest during the month of August. As of August 15th, there was short interest totaling 101,500 shares, adeclineof75.5% from the July 31st total of 415,100 shares. Approximately6.8% of the shares of the company are sold short. Based on an average daily volume of 667,900 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 667,900 shares, the days-to-cover ratio is presently 0.2 days. Approximately6.8% of the shares of the company are sold short.

Avalon GloboCare Stock Performance

Avalon GloboCare stock opened at $2.03 on Wednesday. The business’s 50-day simple moving average is $2.39 and its two-hundred day simple moving average is $3.75. The company has a market cap of $7.80 million, a PE ratio of -0.10 and a beta of 0.02. Avalon GloboCare has a fifty-two week low of $1.87 and a fifty-two week high of $11.66.

Avalon GloboCare (NASDAQ:ALBT) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter. The business had revenue of $0.35 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.